No products in the cart.
Pre-made Keliximab benchmark antibody (Whole mAb, anti-CD4 therapeutic antibody, Anti-IMD79/OKT4D Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-881
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-CD4 therapeutic antibody (Pre-made Keliximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Izokibep has been specifically designed to utilize the strengths of Affibody’s technology platform to create a very small protein drug (18 kDa, approximately one eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM, approximately 1000X of a typical IL-17 antibody) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin. These features lead to the potential for best-in-class efficacy in a convenient, less frequent and at-home subcutaneous administration.
| Products Name (INN Index) | Pre-Made Keliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody |
|---|---|
| INN Name | keliximab |
| Target | CD4 |
| Format | Whole mAb |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – lambda |
| VD LC | IgG1 – lambda |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Biogen,?Inc. (Cambridge MA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD4 |
| Package |
Previous slide
Next slide
